The Reality is This: Unique Efficacy and Safety
Fact is, no other Alzheimer's drug, approved, in testing, or failed, has the unique dual combination of outcomes matching or exceeding Anavex 2-73:
a) profound efficacy, where Alzheimer's patients either remain at baseline cognition levels, or actually increase cognition,
and,
b) profound safety profile, absent any Stage 4 and 5 adverse events (side effects), with the lesser adverse events mild and non-disqualifying (headaches, upset stomach, and the like).